Cargando…

Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein

Debulking surgery followed by chemotherapy are the standard of care for high-grade serous carcinoma. After an initial good response to treatment, the majority of patients relapse with a chemoresistant profile, leading to a poor overall survival. Chemotherapy regimens used in high-grade serous carcin...

Descripción completa

Detalles Bibliográficos
Autores principales:	Nunes, Mariana, Silva, Patrícia M. A., Coelho, Ricardo, Pinto, Carla, Resende, Albina, Bousbaa, Hassan, Almeida, Gabriela M., Ricardo, Sara
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2021
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8566917/ https://www.ncbi.nlm.nih.gov/pubmed/34745981 http://dx.doi.org/10.3389/fonc.2021.752127

Ejemplares similares

Corrigendum: Generation of Two Paclitaxel-Resistant High-Grade Serous Carcinoma Cell Lines With Increased Expression of P-Glycoprotein
por: Nunes, Mariana, et al.
Publicado: (2022)

Pitavastatin and Ivermectin Enhance the Efficacy of Paclitaxel in Chemoresistant High-Grade Serous Carcinoma
por: Nunes, Mariana, et al.
Publicado: (2022)

Evaluation of mitochondrial biogenesis and ROS generation in high-grade serous ovarian cancer
por: Koc, Zeynep C., et al.
Publicado: (2023)

The Antineoplastic Effect of Carboplatin Is Potentiated by Combination with Pitavastatin or Metformin in a Chemoresistant High-Grade Serous Carcinoma Cell Line
por: Nunes, Mariana, et al.
Publicado: (2022)

Antitumoral Effect of Plocabulin in High Grade Serous Ovarian Carcinoma Cell Line Models
por: Heredia-Soto, Victoria, et al.
Publicado: (2022)

Characterizing high-grade serous papillary carcinoma of tunica vaginalis
por: Qu, Liang G., et al.
Publicado: (2019)

Genetic Evidence for Early Peritoneal Spreading in Pelvic High-Grade Serous Cancer
por: Chien, Jeremy, et al.
Publicado: (2018)

The multiple combination of Paclitaxel, Ramucirumab and Elacridar reverses the paclitaxel-mediated resistance in gastric cancer cell lines
por: Schirizzi, Annalisa, et al.
Publicado: (2023)

Advances in Tumor Screening, Imaging, and Avatar Technologies for High-Grade Serous Ovarian Cancer
por: Ohman, Anders W., et al.
Publicado: (2014)

High-Grade Serous Carcinoma Resulting From Rectal Endometriosis and Complicated With Ovarian Cancer
por: Song, Li, et al.
Publicado: (2019)

Nomograms of Combining MRI Multisequences Radiomics and Clinical Factors for Differentiating High-Grade From Low-Grade Serous Ovarian Carcinoma
por: Li, Cuiping, et al.
Publicado: (2022)

Discovery and validation of serum glycoprotein biomarkers for high grade serous ovarian cancer
por: Dutt, Mriga, et al.
Publicado: (2023)

Targeting Aurora A Kinase (AAK) in Platinum-Resistant High Grade Serous Ovarian Cancer
por: Ganapathi, Ram N., et al.
Publicado: (2020)

Nomograms to Predict the Density of Tumor-Infiltrating Lymphocytes in Patients With High-Grade Serous Ovarian Cancer
por: Dai, Danian, et al.
Publicado: (2021)

Ascitic Senescent T Cells Are Linked to Chemoresistance in Patients With Advanced High-Grade Serous Ovarian Cancer
por: Zhang, Jie, et al.
Publicado: (2022)

Investigating the effect of optimal cytoreduction in the context of platinum sensitivity in high‐grade serous ovarian cancer
por: Cardillo, Nicholas, et al.
Publicado: (2022)

Stage, treatment and survival of low‐grade serous ovarian carcinoma in the Netherlands: A nationwide study
por: De Decker, Koen, et al.
Publicado: (2023)

Role of integrins in the metastatic spread of high-grade serous ovarian cancer
por: Krajnak, Slavomir, et al.
Publicado: (2021)

Establishment and characterization of a novel ovarian high-grade serous carcinoma cell line—IPO43
por: Silva, Fernanda, et al.
Publicado: (2022)

Modeling Platinum Sensitive and Resistant High-Grade Serous Ovarian Cancer: Development and Applications of Experimental Systems
por: Cunnea, Paula, et al.
Publicado: (2014)

Reversing Platinum Resistance in High-Grade Serous Ovarian Carcinoma: Targeting BRCA and the Homologous Recombination System
por: Wiedemeyer, W. Ruprecht, et al.
Publicado: (2014)

Spectrum of TP53 Mutations in BRCA1/2 Associated High-Grade Serous Ovarian Cancer
por: Boyarskikh, Ulyana A., et al.
Publicado: (2020)

Phenethyl Isothiocyanate Enhances the Cytotoxic Effects of PARP Inhibitors in High-Grade Serous Ovarian Cancer Cells
por: Jia, Yaxun, et al.
Publicado: (2022)

Single-Cell Proteomics Analysis of Recurrent Low-Grade Serous Ovarian Carcinoma and Associated Brain Metastases
por: Pejovic, Tanja, et al.
Publicado: (2022)

Modeling High-Grade Serous Carcinoma: How Converging Insights into Pathogenesis and Genetics are Driving Better Experimental Platforms
por: Jones, Paul Michael, et al.
Publicado: (2013)

Low Expression of Claudin-7 as Potential Predictor of Distant Metastases in High-Grade Serous Ovarian Carcinoma Patients
por: Romani, Chiara, et al.
Publicado: (2020)

Immune Modeling Analysis Reveals Immunologic Signatures Associated With Improved Outcomes in High Grade Serous Ovarian Cancer
por: James, Nicole E., et al.
Publicado: (2021)

Clinically Interpretable Radiomics-Based Prediction of Histopathologic Response to Neoadjuvant Chemotherapy in High-Grade Serous Ovarian Carcinoma
por: Rundo, Leonardo, et al.
Publicado: (2022)

Incidence of pelvic high-grade serous carcinoma after isolated STIC diagnosis: A systematic review of the literature
por: Linz, Valerie Catherine, et al.
Publicado: (2022)

Promoter Methylation of the MGRN1 Gene Predicts Prognosis and Response to Chemotherapy of High-Grade Serous Ovarian Cancer Patients
por: Li, Xiao-fei, et al.
Publicado: (2021)

Preoperative CT-based deep learning model for predicting overall survival in patients with high-grade serous ovarian cancer
por: Zheng, Yawen, et al.
Publicado: (2022)

Diagnostic and prognostic role of circulating neutrophil extracellular trap markers and prekallikrein in patients with high-grade serous ovarian cancer
por: Kim, Jisoo G., et al.
Publicado: (2022)

Primary high-grade serous ovarian cancer cells are sensitive to senescence induced by carboplatin and paclitaxel in vitro
por: Uruski, Paweł, et al.
Publicado: (2021)

Comparing Paclitaxel–Carboplatin with Paclitaxel–Cisplatin as the Front-Line Chemotherapy for Patients with FIGO IIIC Serous-Type Tubo-Ovarian Cancer
por: Huang, Chen-Yu, et al.
Publicado: (2020)

Prenylated Chalcone 2 Acts as an Antimitotic Agent and Enhances the Chemosensitivity of Tumor Cells to Paclitaxel
por: Fonseca, Joana, et al.
Publicado: (2016)

A New Spontaneously Transformed Syngeneic Model of High-Grade Serous Ovarian Cancer with a Tumor-Initiating Cell Population
por: McCloskey, Curtis W., et al.
Publicado: (2014)

Development of a Genomic Signatures-Based Predictor of Initial Platinum-Resistance in Advanced High-Grade Serous Ovarian Cancer Patients
por: Li, Yuan, et al.
Publicado: (2021)

Development and Validation of an Immune-Related Gene-Pair Model of High-Grade Serous Ovarian Cancer After Platinum-Based Chemotherapy
por: Lin, Jiaxing, et al.
Publicado: (2021)

Establish of an Initial Platinum-Resistance Predictor in High-Grade Serous Ovarian Cancer Patients Regardless of Homologous Recombination Deficiency Status
por: Li, Yongmei, et al.
Publicado: (2022)

Comparative analysis between high-grade serous ovarian cancer and healthy ovarian tissues using single-cell RNA sequencing
por: Zhang, Xiao, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_p703rdps12u34muvc4k3hdqnq8